<s>[INST] The next text is a question of a member of the European parliament:"There have been many instances of atypical antipsychotic drugs marketed in Europe — such as Zyprexa (Olanzapine) — producing dangerous side-effects not mentioned in the accompanying leaflet. They include a number of particularly severe side-effects, such as loss of suppleness, a slowing-down of reflexes, increased anxiety, excessive weight gain, reduced libido, an increased risk of diabetes and the danger of death from even a mild heart attack, loss of self-confidence, a reduced capacity to take decisions, loss of volition and depression. Since most of the drugs consist of recently introduced compounds, there are as yet no long-term studies to show their positive and negative consequences. Furthermore, both Directive92/27/EEC(1) on the labelling of medicinal products for human use and on package leaflets and Directive2001/83/EC(2) on the Community code relating to medicinal products for human use specifically state that package leaflets must contain certain information, including a description of all side-effects. Finally, in the United States around 8000 patients have brought legal proceedings against Eli Lilly, the pharmaceutical company that produces the antipsychotic Zyprexa. They complained of the lack of detailed warnings about a number of the drug’s side-effects and the manufacturer has paid out USD690million in order to settle most of the cases involving the drug.  Can the Commission say what measures it will take with regard to drugs such as Zyprexa (Olanzapine) that do not meet Community legal requirements regarding warnings about side-effects that may seriously harm the physical and mental health of European citizens?    (1)OJ L 113, 30.4.1992, p. 8.  (2)OJ L 311, 28.11.2001, p. 67."
Analyze carefully the text and assign it to the most relevant policy area among those listed below. Do not explain your answer and return only a number.
Policy area numbers: 1 = Macroeconomics
2 = Civil Rights, Minority Issues and Civil Liberties
3 = Health
4 = Agriculture and Fisheries
5 = Labour, employment and pensions
6 = Education
7 = Environment
8 = Energy
9 = Immigration
10 = Transportation
12 = Law and Crime
13 = Social welfare
14 = Regional and Urban issues and Planning
15 = Banking, finance and domestic commerce issues
16 = Defence
17 = Space, science, technology, and communications issues
18 = Foreign trade
19 = International affairs and foreign aid
20 = Governance and government
21 = Public Lands, Water Management and Territorial Issues
23 = Culture and media
[/INST]. Answer = [3]. </s>
There have been many instances of atypical antipsychotic drugs marketed in Europe — such as Zyprexa (Olanzapine) — producing dangerous side-effects not mentioned in the accompanying leaflet. They include a number of particularly severe side-effects, such as loss of suppleness, a slowing-down of reflexes, increased anxiety, excessive weight gain, reduced libido, an increased risk of diabetes and the danger of death from even a mild heart attack, loss of self-confidence, a reduced capacity to take decisions, loss of volition and depression. Since most of the drugs consist of recently introduced compounds, there are as yet no long-term studies to show their positive and negative consequences. Furthermore, both Directive92/27/EEC(1) on the labelling of medicinal products for human use and on package leaflets and Directive2001/83/EC(2) on the Community code relating to medicinal products for human use specifically state that package leaflets must contain certain information, including a description of all side-effects. Finally, in the United States around 8000 patients have brought legal proceedings against Eli Lilly, the pharmaceutical company that produces the antipsychotic Zyprexa. They complained of the lack of detailed warnings about a number of the drug’s side-effects and the manufacturer has paid out USD690million in order to settle most of the cases involving the drug.  Can the Commission say what measures it will take with regard to drugs such as Zyprexa (Olanzapine) that do not meet Community legal requirements regarding warnings about side-effects that may seriously harm the physical and mental health of European citizens?    (1)OJ L 113, 30.4.1992, p. 8.  (2)OJ L 311, 28.11.2001, p. 67.